MedTrace Logo

Administration of DHEA in Patients With Poor Response to Ovarian Stimulation for IVF

NCT02099916 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2014-09-10

No results posted yet for this study

Summary

Poor responders to ovarian stimulation represents one of the most frustrating problems in reproductive medicine. The investigators hypothesize that ovarian response of those patients could improve by treating these patients with 25 mg DHEA tid for 12 weeks prior to stimulation.

Conditions

  • Efficacy of DHEA
  • Pregnancy Rate
  • Diminished Ovarian Reserve
  • Changes in AMH

Interventions

DRUG

gonadotropins plus DHEA

Women in the DHEA group will received 25 mg of DHEA three times a day for at least 12 weeks.

DRUG

Gonadotropins

All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.

Sponsors & Collaborators

  • Lito Maternity Hospital

    collaborator OTHER

  • University of Athens

    lead OTHER

Principal Investigators

  • Nikos Vlahos, AssProfessor · University of Athens, 2nd Department of Obstetrics and Gynecology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2014-12-31
Completion
2015-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02099916 on ClinicalTrials.gov